Relevant bibliographies by topics / Cholinesterase Inhibitor

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Cholinesterase Inhibitor'

Author: Grafiati
Published: 4 June 2021
Last updated: 26 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cholinesterase Inhibitor.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cholinesterase Inhibitor"

1

Dehnabi, Manijeh, Açelya Mavideniz, Tugba Ercetin, and Hayrettin Ozan Gülcan. "Synthesis of 7-(3-(4-(2,3-dichlorophenyl)piperazin-1-yl)propoxy)-3,4-dihydroquinolin-2(1H)-one and Screening Its Cholinesterase Inhibitor Properties." EMU Journal of Pharmaceutical Sciences 8, no. 1 (2025): 8–13. https://doi.org/10.54994/emujpharmsci.1697699.

Full text
Abstract:
Aripiprazole is a well-known atypical antipsychotic drug [i.e., 7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one]. The pharmacological effects of aripiprazole are primarily attributed to its partial agonist activity at dopamine and serotonin receptors, although the exact mechanism of action remains unclear. However, it is generally accepted that aripiprazole exerts its therapeutic effects by modulating dopaminergic and serotoninergic neurotransmission. This study aimed to synthesize a modified derivative of aripiprazole and to investigate the cholinesterase inhi
APA, Harvard, Vancouver, ISO, and other styles
2

Smyrska-Wieleba, Natalia, and Tomasz Mroczek. "Natural Inhibitors of Cholinesterases: Chemistry, Structure–Activity and Methods of Their Analysis." International Journal of Molecular Sciences 24, no. 3 (2023): 2722. http://dx.doi.org/10.3390/ijms24032722.

Full text
Abstract:
This article aims to provide an updated description and comparison of the data currently available in the literature (from the last 15 years) on the studied natural inhibitors of cholinesterases (IChEs), namely, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). These data also apply to the likely impact of the structures of the compounds on the therapeutic effects of available and potential cholinesterase inhibitors. IChEs are hitherto known compounds with various structures, activities and origins. Additionally, multiple different methods of analysis are used to determine the cho
APA, Harvard, Vancouver, ISO, and other styles
3

Hwang, Jayeong, Kumju Youn, Yeongseon Ji, et al. "Biological and Computational Studies for Dual Cholinesterases Inhibitory Effect of Zerumbone." Nutrients 12, no. 5 (2020): 1215. http://dx.doi.org/10.3390/nu12051215.

Full text
Abstract:
Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) mediate the degradation of acetylcholine (ACh), a primary neurotransmitter in the brain. Cholinergic deficiency occurs during the progression of Alzheimer’s disease (AD), resulting in widespread cognitive dysfunction and decline. We evaluated the potential effect of a natural cholinesterase inhibitor, zerumbone, using in vitro target enzyme assays, as well as in silico docking and ADMET (absorption, distribution, metabolism, excretion, and toxicity) simulation. Zerumbone showed a predominant cholinesterase inhibitory property with IC
APA, Harvard, Vancouver, ISO, and other styles
4

Coulson, Brett S., Brett S. Coulson, Stephen G. Fenner, and Osvaldo P. Almeida. "Successful Treatment of Behavioural Problems in Dementia Using a Cholinesterase Inhibitor: The Ethical Questions." Australian & New Zealand Journal of Psychiatry 36, no. 2 (2002): 259–62. http://dx.doi.org/10.1046/j.1440-1614.2002.00977.x.

Full text
Abstract:
Objective: To review the effect of cholinesterase inhibitors on the behavioural and neuropsychiatric symptoms of dementia and discuss the current clinical guidelines for the prescription of cholinesterase inhibitors in Australia. Method: This paper reports the case of a patient with clinical diagnosis of dementia with lewy bodies (DLB) who was referred to an old age psychiatry service for the treatment of severe visual hallucinations and behavioural problems. Results: Pharmacological treatment with olanzapine produced marked parkinsonism, agitation and confusion. A cholinesterase inhibitor, do
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Yao, Yaoyao Bian, Yuan Sun, et al. "Identification of 4-aminoquinoline core for the design of new cholinesterase inhibitors." PeerJ 4 (July 7, 2016): e2140. http://dx.doi.org/10.7717/peerj.2140.

Full text
Abstract:
Inhibition of acetylcholinesterase (AChE) using small molecules is still one of the most successful therapeutic strategies in the treatment of Alzheimer’s disease (AD). Previously we reported compound T5369186 with a core of quinolone as a new cholinesterase inhibitor. In the present study, in order to identify new cores for the designing of AChE inhibitors, we screened different derivatives of this core with the aim to identify the best core as the starting point for further optimization. Based on the results, we confirmed that only 4-aminoquinoline (compound 04 and 07) had cholinesterase inh
APA, Harvard, Vancouver, ISO, and other styles
6

Koay, Yee-Hui, Alireza Basiri, Vikneswaran Murugaiyah, and Kit-Lam Chan. "Isocorilagin, a Cholinesterase Inhibitor from Phyllanthus niruri." Natural Product Communications 9, no. 4 (2014): 1934578X1400900. http://dx.doi.org/10.1177/1934578x1400900423.

Full text
Abstract:
Drugs that have dual inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) produce better clinical efficacy against Alzheimer's disease (AD) than those that selectively inhibit one enzyme. A dual cholinesterase inhibitory-guided fractionation of Phyllanthus niruri leaves afforded isocorilagin, a bioactive tannin possessing good inhibitory activities against AChE (IC50: 0.49 μM) and BChE (IC50: 4.20 μM). Interestingly, isocorilagin was relatively 2- to 3-fold more potent than galanthamine, the clinically used inhibitor. The kinetic analyses suggested that isocorilagin was a
APA, Harvard, Vancouver, ISO, and other styles
7

Petroianu, G. A., A. Schmitt, K. Arafat, and M. Y. Hasan. "Weak Inhibitors Protect Cholinesterases from Stronger Inhibitors (Dichlorvos): In Vitro Effect of Tiapride." International Journal of Toxicology 24, no. 2 (2005): 79–86. http://dx.doi.org/10.1080/10915810590921360.

Full text
Abstract:
Metoclopramide is a benzamide dopamine receptor antagonist and serotonine receptor agonist widely used as an antiemetic and gastric prokinetic drug. In addition, metoclopramide is a weak and reversible inhibitor of cholinesterases. The authors have previously shown that metoclopramide has a cholinesterase protective effect against inhibition by organophosphates (OPs). The putative mode of protective action of metoclopramide is, when administered in excess, competion for the active site of the enzyme with the more potent OP. In the present paper the authors present their results using another b
APA, Harvard, Vancouver, ISO, and other styles
8

Nordberg, Agneta, Taher Darreh-Shori, Elaine Peskind, et al. "Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients." Current Alzheimer Research 6, no. 1 (2009): 4–14. http://dx.doi.org/10.2174/156720509787313961.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Knuepfer, Mark M., and Qi Gan. "Role of cholinergic receptors and cholinesterase activity in hemodynamic responses to cocaine in conscious rats." American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 276, no. 1 (1999): R103—R112. http://dx.doi.org/10.1152/ajpregu.1999.276.1.r103.

Full text
Abstract:
It has been suggested that toxicity to cocaine is related to the relative rate of cocaine metabolism by cholinesterases and to activation of cholinergic receptors either directly or by reflex mechanisms. We examined these possibilities by altering cholinesterase activity and blocking cholinergic receptors in rats prone or resistant to cocaine-induced cardiovascular toxicity. Rats were instrumented with a pulsed Doppler flow probe on the ascending aorta for measurement of cardiac output and cannulated for arterial pressure and heart rate determination. In conscious rats, cocaine (5 mg/kg iv) el
APA, Harvard, Vancouver, ISO, and other styles
10

Mlakić, Milena, Ivan Faraho, Ilijana Odak, et al. "Cholinesterase Inhibitory and Anti-Inflammatory Activity of the Naphtho- and Thienobenzo-Triazole Photoproducts: Experimental and Computational Study." International Journal of Molecular Sciences 24, no. 19 (2023): 14676. http://dx.doi.org/10.3390/ijms241914676.

Full text
Abstract:
New 1,2,3-triazolo(thieno)stilbenes were synthesized as mixtures of isomers and efficiently photochemically transformed to their corresponding substituted thienobenzo/naphtho-triazoles in high isolated yields. The resulting photoproducts were studied as acetyl- (AChE) and butyrylcholinesterase (BChE) inhibitors without or with interconnected inhibition potential of TNF-α cytokine production. The most promising anti-inflammatory activity was shown again by naphtho-triazoles, with a derivative featuring 4-pentenyl substituents exhibiting notable potential as a cholinesterase inhibitor. To identi
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Cholinesterase Inhibitor"

1

Ahtyamova, Daria. "Cholinesterase inhibitor: pharmacological application." Thesis, Київський національний університет технологій та дизайну, 2019. https://er.knutd.edu.ua/handle/123456789/13033.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yau, Kenneth Kwok-Chi. "Assessing and predicting treatment responses to cholinesterase inhibitor pharmacotherapy in Alzheimer's disease." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 2000. http://www.collectionscanada.ca/obj/s4/f2/dsk1/tape4/PQDD_0015/MQ54172.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Lee, David. "Age-Related Differences in In-vitro Sensitivity to Inhibition of Human Red Blood Cell Acetylcholinesterase and Plasma Butyrylcholinesterase by the Cholinesterase Inhibitors Physostigmine (PHYS), Pyridostigmine (PYR), Donepezil (DON) and Galantamine (GAL)." VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1937.

Full text
Abstract:
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder, characterized clinically by a progressive loss of memory, cognitive function, ability to care for oneself and psychiatric symptoms. First-line agents for the treatment of AD are ChE inhibitors (DON, GAL), whose modest clinical efficacy and the high incidence of dose-limiting toxicities limit their clinical utility. In addition to AD, ChE inhibitors (PYR) are used for other medical conditions, such as myasthenia gravis (MG). Furthermore, ChE inhibitors (PYR) are used by military personnel prophylactically if impendin
APA, Harvard, Vancouver, ISO, and other styles
4

Spowart-Manning, Laura. "The evaluation of behavioural tasks and animal models of Alzheimer's disease for assessing putative cognition enhancers, using a cholinesterase inhibitor as reference compound." Thesis, University of Bristol, 2001. http://hdl.handle.net/1983/09e768fe-f64c-47c0-b4d4-d0a19b8ff23d.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Costa, Michael Daniel da. "Efeito da N-acetilcisteína no déficit cognitivo induzido pela estreptozotocina em camundongo." Universidade Federal de Santa Maria, 2016. http://repositorio.ufsm.br/handle/1/4500.

Full text
Abstract:
Conselho Nacional de Desenvolvimento Científico e Tecnológico<br>Cognitive impairment is a mental disorder which is associated with neurodegenerative diseases such as Alzheimer's disease (AD), which is the most common form of dementia. Currently there are no consistent evidence who allow support any measure for the prevention of this disease (DAVIGLUS et al., 2010). As for its treatment, there are methods which can provide relative relief of the symptoms, however, only of palliative nature. Thus, this study aimed to evaluate the n-acetylcysteine (NAC), a molecule with neuroprotective propertie
APA, Harvard, Vancouver, ISO, and other styles
6

Bentley, P. I. "Effects of cholinesterase inhibition on brain function." Thesis, University College London (University of London), 2011. http://discovery.ucl.ac.uk/1301395/.

Full text
Abstract:
Pharmacological-functional imaging provides a non-invasive method by which the actions of neurotropic drugs on the human brain can be explored. Simply put, it assesses how neural activity patterns associated with cognitive functions of interest are modified by a drug challenge. Since one of the most widely-used cognitive-enhancing drugs in clinical practice are cholinesterase inhibitors, this thesis applies pharmacological functional imaging to the question of understanding how such drugs work - both in healthy people and dementia. The experiments in this thesis describe how brain activations
APA, Harvard, Vancouver, ISO, and other styles
7

Hudkins, Robert Lee. "New Antimuscarinic Agents for Improved Treatment of Poisoning by Cholinesterase Inhibitors." VCU Scholars Compass, 1988. http://scholarscompass.vcu.edu/etd/5074.

Full text
Abstract:
Poisoning by organophosphate cholinesterase inhibitors results in a rapid rise in acetylcholine (ACh) in the synapse and many pronounced pharmacological effects in numerous tissues in the body. The treatment for organophosphorus poisoning involves administration of a cholinesterase—reactivating oxime to restore the activity of the cholinesterase and an antimuscarinic agent to block the response to the excess ACh. Presently atropine is the standard antimuscarinic agent used clinically as an antidote. This research was directed toward finding an antimuscarinic agent better than atropine as an an
APA, Harvard, Vancouver, ISO, and other styles
8

Darreh-Shori, Taher. "Molecular changes of acetylcholinesterase and butyrylcholinesterase in Alzheimer patients during the natural couse of the disease and treatment with cholinesterase inhibitors : insight into neurochemical mechanisms affecting the progression of the disease /." Stockholm, 2006. http://diss.kib.ki.se/2006/91-7140-547-X/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Moye, John K. "Use of a homing pigeon (Columbia livia) model to assess the effects of cholinesterase inhibiting pesticides on non-target avian species." abstract and full text PDF (UNR users only), 2008. http://0-gateway.proquest.com.innopac.library.unr.edu/openurl?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:dissertation&res_dat=xri:pqdiss&rft_dat=xri:pqdiss:1460766.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

ELETUFE, PIERRE. "Pancreatites par intoxications aux insecticides inhibiteurs de cholinesterases : a propos de trois observations ; revue de la litterature." Amiens, 1990. http://www.theses.fr/1990AMIEM065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Cholinesterase Inhibitor"

1

Ezio, Giacobini, ed. Cholinesterases and cholinesterase inhibitors. Martin Dunitz, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Yau, Kenneth Kwok Chi. Assessing and predicting treatment responses to cholinesterase inhibitor pharmacotherapy in Alzheimer's disease. National Library of Canada, 2000.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

International Meeting on Cholinesterases (3rd 1990 La Grande Motte, France). Cholinesterases: Structure, function, mechanism, genetics, and cell biology. American Chemical Society, 1991.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

1935-, Zakut Haim, ed. Human cholinesterases and anticholinesterases. Academic Press, 1993.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Moralev, Serge N. Comparative enzymology of cholinesterases. International University Line, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

(Australia), Materials Research Laboratories, ed. Inhibition of EEL acetylcholinesterase by nerve agents: A stopped-flow study. Dept. of Defence, Materials Research Laboratories, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Ezio, Giacobini, and Becker Robert E, eds. Current research in Alzheimer therapy: Cholinesterase inhibitors. Taylor & Francis, 1988.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Todd, G. Daniel. Draft toxicological profile for diazinon. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Roney, Nickolette. Draft toxicological profile for guthion. U.S. Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

National Institute for Clinical Excellence (Great Britain). Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. National Institute for Clinical Excellence, 2001.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Cholinesterase Inhibitor"

1

Ruiz, Manuel Martín, and Joaquín Herrera Carranza. "Metoclopramide as Inhibitor of Serum Cholinesterase." In Recent Developments in Therapeutic Drug Monitoring and Clinical Toxicology. CRC Press, 2023. http://dx.doi.org/10.1201/9781003418153-33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Weinstock, Marta, Tatyana Poltyrev, Corina Bejar, Yotam Sagi, and Moussa B. H. Youdim. "TV3326, A Novel Cholinesterase and Mao Inhibitor." In Mapping the Progress of Alzheimer’s and Parkinson’s Disease. Springer US, 2002. http://dx.doi.org/10.1007/978-0-306-47593-1_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Yamanishi, Yoshiharu, Hiroo Ogura, Takashi Kosasa, Shin Araki, Yoshio Sawa, and Kiyomi Yamatsu. "Inhibitory Action of E2020, a Novel Acetylcholinesterase Inhibitor, on Cholinesterase: Comparison with Other Inhibitors." In Basic, Clinical, and Therapeutic Aspects of Alzheimer’s and Parkinson’s Diseases. Springer US, 1990. http://dx.doi.org/10.1007/978-1-4684-5847-3_83.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rogers, Sharon L., Yoshiharu Yamanishi, and Kiyomi Yamatsu. "E2020 — The Pharmacology of a Piperidine Cholinesterase Inhibitor." In Cholinergic Basis for Alzheimer Therapy. Birkhäuser Boston, 1991. http://dx.doi.org/10.1007/978-1-4899-6738-1_33.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Evtugyn, Gennady, Ravil Younusov, and Alexey Ivanov. "Nanomaterials in the Cholinesterase Biosensors for Inhibitor Determination." In Portable Chemical Sensors. Springer Netherlands, 2012. http://dx.doi.org/10.1007/978-94-007-2872-1_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Janowsky, D. S., S. C. Risch, A. Berkowitz, A. Turken, and M. Drennan. "Central Versus Peripheral Antagonism of Cholinesterase Inhibitor Induced Lethality." In Advances in Behavioral Biology. Springer US, 1986. http://dx.doi.org/10.1007/978-1-4684-5194-8_77.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Yadav, Mange Ram, Prashant R. Murumkar, Karan Joshi, Rahul Barot, and Rasana Yadav. "Approved Cholinesterase Inhibitor-Based Derivatives: Synthesis and Their Biological Evaluation." In Natural Product-based Synthetic Drug Molecules in Alzheimer's Disease. Springer Nature Singapore, 2023. http://dx.doi.org/10.1007/978-981-99-6038-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Patil, Pushpa B., Shweta Patil, Abubakar Mulla, and Pooja Dolli. "Prediction of Anti-Cholinesterase Inhibitor for Alzheimer Disease Using Machine Learning Techniques." In Communications in Computer and Information Science. Springer Nature Switzerland, 2025. https://doi.org/10.1007/978-3-031-86299-1_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Giacobini, Ezio. "Cholinesterase Inhibitors Do More than Inhibit Cholinesterase." In Alzheimer Disease. Birkhäuser Boston, 1997. http://dx.doi.org/10.1007/978-1-4612-4116-4_29.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Anand, Ravi, Richard D. Hartman, Peggy E. Hayes, and Marguirguis Gharabawi. "An Overview of the Development of SDZ ENA 713, A Brain Selective Cholinesterase Inhibitor." In Alzheimer Disease. Birkhäuser Boston, 1997. http://dx.doi.org/10.1007/978-1-4612-4116-4_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cholinesterase Inhibitor"

1

Krunić, Mihajlo J., Jelena Z. Penjišević, Slađana Kostić-Rajačić, Vladimir B. Šukalović, Deana B. Andrić, and Ivana I. Jevtić. "Pyrazole/tacrine derivatives as potential cholinesterase inhibitors." In 2nd International Conference on Chemo and Bioinformatics. Institute for Information Technologies, University of Kragujevac, 2023. http://dx.doi.org/10.46793/iccbi23.567k.

Full text
Abstract:
Two new tacrine/pyrazole conjugates were designed, synthesized, and pharmacologically evaluated for their inhibitory activity toward acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE). A scalable and cost-efficient synthetic route was developed, and key reaction steps for the synthesis of compounds 4a,b were nucleophilic substitution of α-aroylketene dithioacetals with tacrine intermediates, followed by cyclocondensation of respective N,S-acetals with hydrazine hydrate. The preliminary pharmacological evaluation revealed high inhibitory activities of 4a,b toward AChE (180 and 259 nM
APA, Harvard, Vancouver, ISO, and other styles
2

Yong, Seng Kok, Loke Weng Keong, Moochhala Shabbir, and Jon Deoon Lee. "Nonlinear mixed effects pharmacokinetic/pharmacodynamic analysis of the cholinesterase inhibitor pyridostigmine bromide in Chinese males." In 2009 International Conference on Biomedical and Pharmaceutical Engineering (ICBPE). IEEE, 2009. http://dx.doi.org/10.1109/icbpe.2009.5384078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Antonijević, Marko, Žiko Milanović, Edina Avdović, Dušica Simijonović, and Zoran Marković. "ANOTHER LOOK AT THE BIOLOGICAL ROLES OF A PLANT ALKALOID-BERBERINE." In XXVII savetovanje o biotehnologiji. University of Kragujevac, Faculty of Agronomy, 2022. http://dx.doi.org/10.46793/sbt27.455a.

Full text
Abstract:
For millennia, berberine extracts or berberine itself has been the effective traditional drug with wide application due to its broad spectrum of antibiotic activity. A significant aspect of the berberine’s physiological activity that is often overlooked is the ability to go through the blood-brain barrier and has an impact on different processes and irregularities in the brain such as dementia and Alzheimer’s disease. Potential inhibitory activity towards enzymes for which is believed to be involved in these diseases, in this paper is confirmed by molecular docking simulations. Binding energie
APA, Harvard, Vancouver, ISO, and other styles
4

Fassa, Anaclaudia G., Neice Muller X Faria, Rodrigo D. Meucci, Nadia S. Fiori, Maria Laura V Carret, and Carlos Augusto Mello Silva. "1369 Is plasma cholinesterase a reliable biomarker in long-term exposure to cholinesterase inhibitors?" In 32nd Triennial Congress of the International Commission on Occupational Health (ICOH), Dublin, Ireland, 29th April to 4th May 2018. BMJ Publishing Group Ltd, 2018. http://dx.doi.org/10.1136/oemed-2018-icohabstracts.1323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

González-Burgos, Elena, Noelia Fraga Matías, Isabel Maria Ureña Vacas, and M. Pilar Gómez-Serranillos. "Biological evaluation of Cetrarioid clade as cholinesterase inhibitors." In 5th International Electronic Conference on Medicinal Chemistry. MDPI, 2019. http://dx.doi.org/10.3390/ecmc2019-06316.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

ZOMER, G., M. R. J. HAMZINK, and L. BIJLSMA. "CHOLINESTERASE INHIBITORS MEASURED WITH A CHEMILUMINESCENCE SYSTEM BASED ON GZ-11." In Bioluminescence and Chemiluminescence - Progress and Current Applications - 12th International Symposium on Bioluminescence (BL) and Chemiluminescence (CL). WORLD SCIENTIFIC, 2002. http://dx.doi.org/10.1142/9789812776624_0105.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Cejudo, BM Muñoz, MR Cantudo Cuenca, MA Mora Mora, G. Fernández Martínez, and MT Cantal Sánchez. "4CPS-177 Anticholinergic risk in elderly patients with dementia taking cholinesterase inhibitors." In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.267.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Makhaeva, G. F., N. V. Kovaleva, S. V. Lushchekina, et al. "MULTITARGET AGENTS FOR THE TREATMENT OF ALZHEIMER’S DISEASE BASED ON CHOLINESTERASE INHIBITORS." In MedChem-Russia 2021. 5-я Российская конференция по медицинской химии с международным участием «МедХим-Россия 2021». Издательство Волгоградского государственного медицинского университета, 2021. http://dx.doi.org/10.19163/medchemrussia2021-2021-59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Ailabouni, Nagham J., Wade Thompson, Sarah N. Hilmer, et al. "004 Co-designing a consult patient decision aid for deprescribing cholinesterase inhibitors." In 12th International Shared Decision Making Conference. BMJ Publishing Group Ltd, 2024. http://dx.doi.org/10.1136/bmjebm-2024-sdc.4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ridzuan, M. S. M., M. Z. Jaafar, and M. M. Zain. "Quantitative structure-activity relationship (QSAR) modelling of N-aryl derivatives as cholinesterase inhibitors." In 2012 IEEE Symposium on Humanities, Science and Engineering Research (SHUSER). IEEE, 2012. http://dx.doi.org/10.1109/shuser.2012.6269006.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cholinesterase Inhibitor"

1

Koh, John T. Design and Synthesis of Bifunctional Oxime Reactivators of OP- inhibited Cholinesterase. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada602407.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Taylor, Palmer W. Cholinesterase Structure: Identification of Residues and Domains Affecting Organophosphate Inhibition and Catalysis. Defense Technical Information Center, 1998. http://dx.doi.org/10.21236/ada354080.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Taylor, Palmer W. Cholinesterase Structure: Identification of Mechanisms and Residues Involved in Organophosphate Inhibition and Enzyme Reactivation. Defense Technical Information Center, 2005. http://dx.doi.org/10.21236/ada442260.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Taylor, Palmer W. Cholinesterase Structure: Identification of Mechanisms and Residues Involved in Organophosphate Inhibition and Enzyme Reactivation. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada426549.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Taylor, Palmer. Cholinesterase Structure: Identification of Mechanisms and Residues Involved in Organophosphate Inhibition and Enzyme Reactivation. Defense Technical Information Center, 2003. http://dx.doi.org/10.21236/ada417075.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Liu, Miao, Hongan Wang, Jing Lu, et al. Vitamin D supplementation in the treatment of Myasthenia Gravis A protocol for a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, 2022. http://dx.doi.org/10.37766/inplasy2022.9.0129.

Full text
Abstract:
Review question / Objective: The patients should meet the internationally recognized diagnostic criteria for myasthenia gravis and be definitely diagnosed as myasthenia gravis, excluding MG patients caused by congenital, drug and other factors, as well as patients with serious primary diseases, autoimmune diseases or mental diseases. Patients are not restricted by race, region, gender, age, background, course of disease and other factors. We will focus on trials using vitamin D as an intervention at any dose and in any regimen (eg daily/weekly/monthly intake). The control group was routinely g
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Cholinesterase Inhibitor' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography